Medicine
Foundayo 2.5 mg tablet
Foundayo 2.5 mg tablet is a prescription medicine containing Orforglipron for oral use, marketed by Eli Lilly, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store FOUNDAYO at room temperature 20°C to 25°C (68°F to 77°F), excursions…
Key facts
- Active ingredient (INN)
- Orforglipron
- Brand
- Foundayo
- Strength
- 2.5 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- Eli Lilly
- Manufacturer
- Eli Lilly
- Origin register
- US FDA, United States
- Storage
- Store FOUNDAYO at room temperature 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10BJ Glucagon-like peptide-1
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 April 2026
- Identifiers
- RxCUI 2739844, 2739850, 2739852 +7DailyMed set ID 8ac446c5-feba-474f-a103-23facb9b5c62NDC 0002-4503Application NDA220934
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 30 tablet, film coated in 1 bottle | 0002-4503-31 | Eli Lilly | 1 April 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 1 April 2026 | Drugs@FDA |
| EU (EMA) | Opinion | EMA medicines data |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Orforglipron
Clinical summary
Orforglipron is a GLP-1 receptor agonist. It is available as tablets for oral use. MedsAcross supplies Orforglipron for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about OrforglipronFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- FOUNDAYO prescribing information (Eli Lilly) · U.S. National Library of Medicine, DailyMed
Need Foundayo 2.5 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.